DK3810201T3 - GIP/GLP1-agonist-sammensætninger - Google Patents

GIP/GLP1-agonist-sammensætninger Download PDF

Info

Publication number
DK3810201T3
DK3810201T3 DK19739766.4T DK19739766T DK3810201T3 DK 3810201 T3 DK3810201 T3 DK 3810201T3 DK 19739766 T DK19739766 T DK 19739766T DK 3810201 T3 DK3810201 T3 DK 3810201T3
Authority
DK
Denmark
Prior art keywords
gip
agonist compositions
glp1 agonist
glp1
compositions
Prior art date
Application number
DK19739766.4T
Other languages
English (en)
Other versions
DK3810201T5 (da
Inventor
Vincent John Corvari
Christopher Sears Minie
Dinesh Shyandeo Mishra
Ken Kangyi Qian
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=67263049&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3810201(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of DK3810201T3 publication Critical patent/DK3810201T3/da
Publication of DK3810201T5 publication Critical patent/DK3810201T5/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/20—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Emergency Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Fodder In General (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK19739766.4T 2018-06-22 2019-06-14 GIP/GLP1-agonist-sammensætninger DK3810201T5 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862688632P 2018-06-22 2018-06-22
PCT/US2019/037146 WO2019245893A2 (en) 2018-06-22 2019-06-14 Gip/glp1 agonist compositions

Publications (2)

Publication Number Publication Date
DK3810201T3 true DK3810201T3 (da) 2023-06-26
DK3810201T5 DK3810201T5 (da) 2023-08-21

Family

ID=67263049

Family Applications (1)

Application Number Title Priority Date Filing Date
DK19739766.4T DK3810201T5 (da) 2018-06-22 2019-06-14 GIP/GLP1-agonist-sammensætninger

Country Status (34)

Country Link
US (6) US11357820B2 (da)
EP (2) EP3810201B9 (da)
JP (4) JP6896945B2 (da)
KR (4) KR20240060873A (da)
CN (3) CN119424615A (da)
AR (1) AR115542A1 (da)
AU (3) AU2019289110B2 (da)
BR (1) BR112020023452A2 (da)
CA (1) CA3103469C (da)
CL (1) CL2020003359A1 (da)
CR (1) CR20200634A (da)
DK (1) DK3810201T5 (da)
EA (1) EA202092713A1 (da)
EC (1) ECSP20082717A (da)
ES (1) ES2953740T3 (da)
FI (1) FI3810201T3 (da)
HR (1) HRP20230748T1 (da)
HU (1) HUE063059T2 (da)
IL (2) IL279504B (da)
JO (1) JOP20200335B1 (da)
LT (1) LT3810201T (da)
MA (1) MA52965B1 (da)
MD (1) MD3810201T2 (da)
MX (2) MX2020013727A (da)
PE (2) PE20210049A1 (da)
PH (1) PH12020552215A1 (da)
PL (1) PL3810201T3 (da)
PT (1) PT3810201T (da)
RS (1) RS64288B9 (da)
SG (1) SG11202012744UA (da)
SI (1) SI3810201T1 (da)
TW (1) TWI705820B (da)
WO (1) WO2019245893A2 (da)
ZA (1) ZA202007162B (da)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20240485T1 (hr) 2017-08-24 2024-07-05 Novo Nordisk A/S Pripravci glp-1 i njihova upotreba
TWI705820B (zh) * 2018-06-22 2020-10-01 美商美國禮來大藥廠 Gip/glp1促效劑組合物
EP3826662B9 (en) 2018-07-23 2025-02-19 Eli Lilly and Company Method of using a gip/glp1 co-agonist for diabetes
CN120754229A (zh) * 2018-07-23 2025-10-10 伊莱利利公司 使用gip/glp1共激动剂用于治疗的方法
US12459980B2 (en) 2018-07-25 2025-11-04 AskGene Pharma, Inc. IL-21 prodrugs and methods of use thereof
US20220249814A1 (en) * 2018-11-19 2022-08-11 Progenity, Inc. Methods and devices for treating a disease with biotherapeutics
KR20220020879A (ko) 2019-06-12 2022-02-21 에스크진 파마, 아이엔씨. 새로운 il-15 프로드럭 및 이를 사용하는 방법
CN110642935A (zh) * 2019-09-25 2020-01-03 成都奥达生物科技有限公司 一种替瑞帕肽类似物
WO2021142471A1 (en) 2020-01-11 2021-07-15 AskGene Pharma, Inc. Novel masked cytokines and methods of use thereof
TW202228762A (zh) 2020-01-30 2022-08-01 美商美國禮來大藥廠 提派肽(tirzepatide)之治療用途
PE20230819A1 (es) 2020-02-18 2023-05-19 Novo Nordisk As Composiciones y usos de glp-1
CN116171164A (zh) * 2020-10-17 2023-05-26 太阳医药工业有限公司 Glp-1/gip双重激动剂
WO2022159395A1 (en) 2021-01-20 2022-07-28 Viking Therapeutics, Inc. Compositions and methods for the treatment of metabolic and liver disorders
CN118307645A (zh) * 2021-05-28 2024-07-09 广东众生睿创生物科技有限公司 多肽的制备及其应用
MX2024003236A (es) 2021-09-15 2024-06-19 Viking Therapeutics Inc Composiciones y metodos para el tratamiento de trastornos metabolicos y hepaticos.
KR20240068737A (ko) 2021-09-27 2024-05-17 테른스 파마슈티칼스, 인크. Glp-1r 효능제로서의 벤즈이미다졸 카복실산
AU2022375634A1 (en) 2021-10-25 2024-06-06 Terns Pharmaceuticals, Inc. Compounds as glp-1r agonists
MX2024007861A (es) * 2022-01-10 2024-07-09 Jiangsu Hansoh Pharmaceutical Group Co Ltd Composicion farmaceutica estable de agonista de receptor, metodo de preparacion y su aplicacion.
EP4466022A4 (en) * 2022-01-18 2025-12-10 Viking Therapeutics Inc Pharmaceutical Formulations and Methods for the Treatment of Metabolic and Liver Disorders
KR20240150488A (ko) 2022-02-23 2024-10-15 테른스 파마슈티칼스, 인크. Glp-1r 작용제로서의 화합물
CN114949183B (zh) * 2022-05-07 2023-02-28 山东京卫制药有限公司 一种替尔泊肽粉雾剂及其制备方法
KR20250029908A (ko) * 2022-06-30 2025-03-05 일라이 릴리 앤드 캄파니 티르제파티드 조성물 및 용도
JP2025531387A (ja) * 2022-09-23 2025-09-19 ブライトジーン プライベート リミティド Ｇｌｐ－１とｇｉｐの二重受容体アゴニスト医薬組成物及びその用途
KR102942046B1 (ko) * 2022-10-19 2026-03-24 일라이 릴리 앤드 캄파니 보존된 gip/glp 효능제 조성물
CN115651075B (zh) * 2022-12-12 2023-04-11 杭州信海医药科技有限公司 一种Tirzepatide的合成方法
AU2024235143A1 (en) * 2023-03-15 2025-09-11 Viking Therapeutics, Inc. Pharmaceutical compositions and methods for the treatment of metabolic and liver disorders
US20240398794A1 (en) 2023-04-07 2024-12-05 Terns Pharmaceuticals, Inc. COMBINATIONS OF GLP-1R AND THRß AGONISTS AND METHODS OF USE THEREOF
EP4714434A1 (en) * 2023-05-19 2026-03-25 Aulbio Co., Ltd. Microsphere comprising thyrazepatide, method for preparing same, and pharmaceutical composition comprising same
KR102792620B1 (ko) * 2023-06-02 2025-04-11 주식회사 지투지바이오 터제파타이드 또는 이의 약학적으로 허용가능한 염을 포함하는 서방성 미립구 제제 및 이의 제조방법
AU2024368633A1 (en) * 2023-10-25 2026-04-02 Beta Pharma, Inc. Glp1-r/gipr dual peptide agonists and use thereof
WO2025141472A1 (en) * 2023-12-27 2025-07-03 Alembic Pharmaceuticals Limited Stable pharmaceutical compositions comprising tirzepatide
WO2025191149A1 (en) 2024-03-15 2025-09-18 Krka, D.D., Novo Mesto Pharmaceutical composition comprising dual gip and glp-1 receptor agonist
CN120829494A (zh) * 2024-04-18 2025-10-24 苏州星曜坤泽生物制药有限公司 一种glp-1gip类似物、fgf21蛋白、三功能蛋白及其应用
EP4656183A1 (en) 2024-05-31 2025-12-03 Galenicum Health SLU Tirzepatide compositions and preparation method
WO2026059846A1 (en) 2024-09-13 2026-03-19 Eli Lilly And Company Dissolving microneedle patch for transdermal delivery of a peptide
US12465697B1 (en) 2025-02-26 2025-11-11 Genzyme Corporation Medicament delivery device
US12539367B1 (en) 2025-02-26 2026-02-03 Genzyme Corporation Medicament delivery device
US12434008B1 (en) 2025-02-26 2025-10-07 Genzyme Corporation Lock ring for a medicament delivery device
US12420017B1 (en) 2025-02-26 2025-09-23 Genzyme Corporation Damping device for a medicament delivery device

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06247870A (ja) * 1993-02-23 1994-09-06 Ajinomoto Co Inc インターロイキン−６を含有する医薬製剤
NZ250844A (en) 1993-04-07 1996-03-26 Pfizer Treatment of non-insulin dependant diabetes with peptides; composition
JP3723857B2 (ja) * 1998-02-04 2005-12-07 日本ケミカルリサーチ株式会社 ヒト成長ホルモン含有水性医薬組成物
ATE367828T1 (de) * 1998-04-03 2007-08-15 Novartis Vaccines & Diagnostic Igf-enthaltende injizierbare formulierungen enthaltend succinate als puffermittel
ATE424413T1 (de) 2000-06-16 2009-03-15 Lilly Co Eli Analoge des glucagon-ähnlichen peptids-1
US7977376B2 (en) * 2001-06-27 2011-07-12 Novartis Ag Olopatadine formulations for topical nasal administration
AU2002316811A1 (en) 2001-06-28 2003-03-03 Novo Nordisk A/S Stable formulation of modified glp-1
EP1633391B1 (en) 2003-06-03 2011-10-19 Novo Nordisk A/S Stabilized pharmaceutical peptide compositions
TR201906789T4 (tr) * 2003-11-20 2019-05-21 Novo Nordisk As Üretim ve enjeksiyon cihazlarında kullanım için en uygun olan propilen glikol ihtiva eden peptit formülasyonları.
RU2413530C9 (ru) 2004-11-12 2021-05-18 Ново Нордиск А/С Стабильные препараты инсулинотропных пептидов
WO2006051103A2 (en) 2004-11-12 2006-05-18 Novo Nordisk A/S Stable formulations of peptides
EA011166B1 (ru) 2004-12-22 2009-02-27 Эли Лилли Энд Компани Композиции слитых белков-аналогов glp-1
KR20080031394A (ko) * 2005-07-12 2008-04-08 리노보 리미티드 Ｔｇｆ-베타 수퍼패밀리 구성원을 포함하는 약학 조성물
MX2008013216A (es) * 2006-04-14 2008-10-27 Mannkind Corp Formulaciones farmaceuticas de peptido-1 tipo glucagon (glp-1).
US8501693B2 (en) 2006-08-04 2013-08-06 Amylin Pharmaceuticals, Llc Use of exendins and exendin agonists and GLP-1 receptor agonists for altering the concentration of fibrinogen
CN101730523A (zh) 2007-07-10 2010-06-09 伊莱利利公司 GLP-1-Fc融合蛋白质制剂
CN101822822A (zh) * 2009-03-04 2010-09-08 北京德众万全药物技术开发有限公司 一种普兰林肽的药物组合物及其制备方法
EP2528618A4 (en) 2010-01-27 2015-05-27 Univ Indiana Res & Tech Corp GLUCAGON ANTAGONISTE AND GIP AGONISTS CONJUGATES AND COMPOSITIONS FOR THE TREATMENT OF METABOLISM DISEASES AND ADIPOSITAS
EA027032B1 (ru) 2010-03-01 2017-06-30 Эли Лилли Энд Компани Автоматическое инъекционное устройство с замедлителем, включающим смещающий элемент с двойственной функцией
RS56173B1 (sr) * 2011-06-22 2017-11-30 Univ Indiana Res & Tech Corp Koagonisti receptora za glukagon/glp-1 receptora
JP6228187B2 (ja) 2012-05-03 2017-11-08 ジーランド ファーマ アクティーゼルスカブ Ｇｉｐ−ｇｌｐ−１デュアルアゴニスト化合物及び方法
HRP20251088T1 (hr) 2012-07-01 2025-11-07 Novo Nordisk A/S Upotreba dugodjelujućih peptida glp‑1
AR092862A1 (es) * 2012-07-25 2015-05-06 Hanmi Pharm Ind Co Ltd Formulacion liquida de insulina de accion prolongada y un peptido insulinotropico y metodo de preparacion
WO2014081849A1 (en) 2012-11-20 2014-05-30 Phasebio Pharmaceuticals, Inc. Formulations of active agents for sustained release
CN103893744B (zh) 2012-12-24 2017-12-19 杭州九源基因工程有限公司 一种治疗糖尿病的药物制剂及其制备方法
US11045523B2 (en) 2013-04-05 2021-06-29 Novo Nordisk Healthcare Ag Formulation of growth hormone albumin-binder conjugate
US20160136246A1 (en) 2013-06-21 2016-05-19 Novo Nordisk A/S Novel Uses of GLP-1 Receptor Agonists in Patients Treated with Insulin and/or Suffering from Type 1 Diabetes
US10266577B2 (en) 2013-08-15 2019-04-23 Novo Nordisk A/S GLP-1 derivatives, and uses thereof
MX369818B (es) 2013-11-15 2019-11-22 Novo Nordisk As Compuestos selectivos de peptido yy (pyy) y usos de los mismos.
JP6723921B2 (ja) 2014-01-09 2020-07-15 サノフイＳａｎｏｆｉ インスリンアナログおよび／またはインスリン誘導体の、グリセリンを含まない安定化された医薬製剤
WO2016077220A1 (en) * 2014-11-10 2016-05-19 Mb2 Llc Gip/glp-1 co-agonist peptides for human administration
JO3575B1 (ar) * 2015-01-09 2020-07-05 Lilly Co Eli مركبات مساعد مشترك من gip وglp-1
RU2760007C2 (ru) * 2016-05-16 2021-11-22 Интарсия Терапьютикс, Инк. Полипептиды, селективные к рецепторам глюкагона, и способы их применения
WO2018103868A1 (en) 2016-12-09 2018-06-14 Zealand Pharma A/S Acylated glp-1/glp-2 dual agonists
TWI705820B (zh) 2018-06-22 2020-10-01 美商美國禮來大藥廠 Gip/glp1促效劑組合物

Also Published As

Publication number Publication date
FI3810201T3 (fi) 2023-08-17
US20250186544A1 (en) 2025-06-12
ZA202007162B (en) 2025-05-28
JP6896945B2 (ja) 2021-06-30
CA3103469C (en) 2024-04-09
EP3810201B1 (en) 2023-06-07
SI3810201T1 (sl) 2023-08-31
RS64288B9 (sr) 2023-11-30
KR20230058172A (ko) 2023-05-02
JP2025102837A (ja) 2025-07-08
HUE063059T2 (hu) 2023-12-28
CL2020003359A1 (es) 2021-06-25
IL295433B1 (en) 2023-11-01
US20220273762A1 (en) 2022-09-01
MX2020013727A (es) 2021-03-02
WO2019245893A2 (en) 2019-12-26
MA52965B1 (fr) 2023-08-31
US11918623B2 (en) 2024-03-05
JP2021506952A (ja) 2021-02-22
ECSP20082717A (es) 2021-01-29
IL279504B (en) 2022-09-01
BR112020023452A2 (pt) 2021-02-23
MD3810201T2 (ro) 2023-11-30
PE20242299A1 (es) 2024-12-11
JOP20200335A1 (ar) 2020-12-20
DK3810201T5 (da) 2023-08-21
AR115542A1 (es) 2021-01-27
CA3103469A1 (en) 2019-12-26
US12453756B2 (en) 2025-10-28
EA202092713A1 (ru) 2021-04-05
JP7413315B2 (ja) 2024-01-15
AU2019289110B2 (en) 2022-10-06
KR20240060873A (ko) 2024-05-08
EP4257185A3 (en) 2024-01-17
KR20210010572A (ko) 2021-01-27
EP3810201A2 (en) 2021-04-28
JOP20200335B1 (ar) 2024-04-18
US12453755B2 (en) 2025-10-28
US20260053888A1 (en) 2026-02-26
US20240226229A1 (en) 2024-07-11
US11357820B2 (en) 2022-06-14
WO2019245893A3 (en) 2020-03-12
CN119424616A (zh) 2025-02-14
EP3810201B9 (en) 2023-08-02
SG11202012744UA (en) 2021-01-28
MX2025004309A (es) 2025-05-02
CN112312926A (zh) 2021-02-02
AU2024266715A1 (en) 2024-12-19
TWI705820B (zh) 2020-10-01
US20250367253A1 (en) 2025-12-04
HRP20230748T1 (hr) 2023-10-27
US20190388502A1 (en) 2019-12-26
PL3810201T3 (pl) 2023-09-25
PH12020552215A1 (en) 2021-06-28
ES2953740T3 (es) 2023-11-15
JP7700205B2 (ja) 2025-06-30
LT3810201T (lt) 2023-07-25
IL295433B2 (en) 2024-03-01
TW202015717A (zh) 2020-05-01
JP2021167314A (ja) 2021-10-21
IL295433A (en) 2022-10-01
NZ770042A (en) 2024-07-26
PE20210049A1 (es) 2021-01-08
CR20200634A (es) 2021-01-21
KR20250090374A (ko) 2025-06-19
AU2019289110A1 (en) 2021-01-21
CN119424615A (zh) 2025-02-14
CN119424616B (zh) 2025-11-07
AU2022279524A1 (en) 2023-02-02
EP4257185A2 (en) 2023-10-11
RS64288B1 (sr) 2023-07-31
KR102523489B1 (ko) 2023-04-21
PT3810201T (pt) 2023-07-04
IL279504A (en) 2021-01-31
MA52965A (fr) 2021-04-28
JP2024041808A (ja) 2024-03-27

Similar Documents

Publication Publication Date Title
DK3810201T3 (da) GIP/GLP1-agonist-sammensætninger
IL279827A (en) Gip/glp1 co-agonist compounds
IL283692A (en) Novel composition
EP3849598A4 (en) Anti-trem-2 agonist antibodies
DK3890488T3 (da) Herbicide sammensætninger
DK3810587T3 (da) Substituerede alkoxypyridinylindolsulfonamider
EP3853332C0 (en) COMPOSITION
EP3823584A4 (en) DETERGENT COMPOSITION
DK3924443T3 (da) Compositions
EP3882323A4 (en) COMPOSITION
DK3840596T3 (da) Sammensætning
EP3871694A4 (en) COMPOSITION
EP3812426A4 (en) CURABLE COMPOSITION
DK3808747T3 (da) Imidazopyridinon-forbindelse
EP3897866C0 (en) ANTIMICROBIAL COMPOSITION
DK3746054T3 (da) Sammensætninger omfattende berberin
EP3981256A4 (en) COMPOSITION
EP3941942A4 (en) COMPOSITION
EP3954721A4 (en) Composition
EP3914303C0 (en) VIRUCIDAL COMPOSITION
EP3741814C0 (en) COMPOSITION
PT3765379T (pt) Composições
EP3875451A4 (en) TLR8 AGONIST
EP3829532A4 (en) KERATIN COMPOSITIONS
EP3821574C0 (en) Digital isolator